AstraZeneca PLC Ordinary Shares (AZN) Covered Calls
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its primary therapeutic areas include oncology, rare diseases, and biopharmaceuticals, covering cardiovascular, renal, metabolism, respiratory, and immunology. The company operates a vast international manufacturing and research network, delivering innovative treatments for complex diseases to patients in over one hundred countries.
You can sell covered calls on AstraZeneca PLC Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for AZN (prices last updated Mon 4:16 PM ET):
| AstraZeneca PLC Ordinary Shares (AZN) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 194.95 | +0.73 | 188.00 | 196.54 | 1.9M | 30 | 255 |
| Covered Calls For AstraZeneca PLC Ordinary Shares (AZN) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 195 | 3.55 | 192.99 | 1.0% | 30.4% | |
| Apr 17 | 195 | 7.05 | 189.49 | 2.9% | 26.5% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
AstraZeneca operates as a premier innovation-driven healthcare provider. The company specializes in converting complex laboratory breakthroughs into transformative medicines. Its diverse portfolio is built around high-growth segments that provide essential treatments for chronic and life-threatening conditions. Their primary offerings include:
- Oncology: Leading-edge cancer therapies such as Tagrisso, Imfinzi, and Lynparza, alongside next-generation antibody-drug conjugates.
- Cardiovascular, Renal, and Metabolism: Essential medicines like Farxiga that address interconnected chronic conditions.
- Respiratory and Immunology: Advanced biologics and inhaled therapies, including Fasenra and Breztri, for asthma and autoimmune disorders.
- Rare Disease: Specialized treatments for ultra-rare conditions through its Alexion division, focusing on complement system biology.
Competitive Landscape
The biopharmaceutical industry is characterized by intense competition for market share and intellectual property. AstraZeneca competes with other global giants such as Novartis and GSK across several therapeutic categories. In the oncology and immunology spaces, it encounters significant competition from Merck & Co. and Pfizer. Additionally, as the company expands its cardiometabolic and weight management pipeline, it faces rivals like Novo Nordisk and Eli Lilly. For rare disease treatments, the company is often challenged by innovators like Amgen and various biotechnology firms specializing in gene-editing and cell therapy.
Strategic Outlook and Innovation
AstraZeneca is executing a long-term growth strategy centered on doubling its annual revenue by the end of the decade through the launch of dozens of new medicines. A major strategic priority is the onshoring of manufacturing to ensure that medicines sold in North America are produced within the region to mitigate global supply chain risks. Innovation efforts are increasingly focused on AI-discovered drugs and automated R&D workflows, which aim to significantly compress drug discovery timelines and improve clinical success rates. The company is also investing heavily in "AI Factories" for healthcare, using multimodal foundation models to redefine precision medicine in oncology. By leveraging these advanced technologies and expanding its presence in high-density life science hubs, the bank aims to lead the industry in sustainable biopharmaceutical production and patient-centric care.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | KSS covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | OWL covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | USO covered calls | |
Want more examples? AZ Covered Calls | AZO Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
